These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 9499363)

  • 1. 90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/L.
    Tinari N; Natoli C; D'Ostilio N; Ghinelli F; Sighinolfi L; Ortona L; Tamburrini E; Piazza M; Chirianni A; Guerra L; Di Gregorio P; Iacobelli S
    Arch Pathol Lab Med; 1998 Feb; 122(2):178-81. PubMed ID: 9499363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
    Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum levels of soluble tumor necrosis factor receptors as markers for disease progression of human immunodeficiency virus infection].
    Hattori M; Tateyama M; Oishi T; Miyasaka S; Fukutake K
    Rinsho Byori; 1997 Nov; 45(11):1085-90. PubMed ID: 9396350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta2 microglobulin as a surrogate marker for HIV infection: good correlation with CD4 counts.
    Wanchu A; Arora S; Bhatnagar A; Sud A; Bambery P; Singh S
    Indian J Pathol Microbiol; 2004 Apr; 47(2):298-301. PubMed ID: 16295507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters.
    Beld M; Penning M; Lukashov V; McMorrow M; Roos M; Pakker N; van den Hoek A; Goudsmit J
    Virology; 1998 May; 244(2):504-12. PubMed ID: 9601518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
    Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
    Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
    van Leeuwen R; Lange JM; Nijhuis M; Schuurman R; Reiss P; Danner SA; Boucher CA
    Antivir Ther; 1997 Apr; 2(2):79-90. PubMed ID: 11322279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
    AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
    Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
    J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.
    Battegay M; Wirz M; Steuerwald MH; Egger M
    J Intern Med; 1998 Dec; 244(6):479-87. PubMed ID: 9893101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.